SCHEMBL21965241

SCHEMBL21965241

COc1ccc(CNc2ncc(-c3cnn(C)c3)c3c2c(-c2ccc(Oc4ccccc4)cc2)nn3C2CC3CC2N(C(=O)OC(C)(C)C)C3)c(OC)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 5/20 0.36
▸ KDR P35968 2/20 0.36
▸ FGFR3 P22607 1/20 0.36
▸ RET P07949 3/20 0.35
▸ MAPT P10636 2/20 0.34
▸ IRAK1 P51617 1/20 0.34
▸ CYP1A2 P05177 5/20 0.33
▸ CYP3A4 P08684 5/20 0.33
▸ CYP2C19 P33261 5/20 0.33
▸ CYP2C9 P11712 4/20 0.33
▸ ALDH1A1 P00352 3/20 0.33
▸ TSHR P16473 3/20 0.33
▸ HSD17B10 Q99714 3/20 0.33
▸ CYP2D6 P10635 3/20 0.33
▸ LMNA P02545 2/20 0.33
▸ CLK4 Q9HAZ1 2/20 0.33
▸ HIF1A Q16665 2/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ CSF1R P07333 1/20 0.33
▸ PDGFRB P09619 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22009288 0.95 BTK (0.35) BTKKDRFGFR3RETIRAK1
SCHEMBL21903726 0.89 BTK (0.38) BTKMAPTCYP1A2CYP3A4CYP2C19
SCHEMBL21903891 0.87 BTK (0.44) BTKIRAK1
SCHEMBL21903812 0.85 BTK (0.41) BTKMAPTCYP1A2CYP3A4CYP2C19
SCHEMBL28370880 0.84 KDR (0.37) BTKKDRFGFR3MAPTCYP1A2
SCHEMBL22008946 0.81 BTK (0.40) BTK
SCHEMBL21903750 0.81 BTK (0.45) BTK
SCHEMBL31684267 0.81 BTK (0.45) BTK
SCHEMBL21965629 0.80 IRAK1 (0.42) BTKKDRFGFR3RETMAPT
SCHEMBL21903605 0.76 BTK (0.45) BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180496-B2 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2021-11-23 — — US disclosed
EP-3653626-A1 NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Daewoong Pharmaceutical Co., Ltd. (KR) 2020-05-20 — — EP disclosed
US-20200140432-A1 NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2020-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11180496-B2 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same PDCD11, DPYD, G6PC1 BTK 1236/4885KDR 4166/4885FGFR3 2588/4885
US-20200140432-A1 NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME PDCD11, G6PC1, PPM1D BTK 1744/4885KDR 4282/4885FGFR3 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback